


4-(2-(4-(4-[¹⁸F]Fluoro-butyl)-phenyl)ethoxy) quinazoline

[¹⁸F]RP1003

Kam Leung, PhD¹

Created: June 15, 2011; Updated: January 26, 2012.

Chemical name:	4-(2-(4-(4-[¹⁸ F]Fluoro-butyl)-phenyl)ethoxy) quinazoline	
Abbreviated name:	[¹⁸ F]RP1003	
Synonym:		
Agent category:	Compound	
Target:	Mitochondrial complex I (MCI)	
Target category:	Enzyme	
Method of detection:	Positron emission tomography (PET)	
Source of signal:	¹⁸ F	
Activation:	No	
Studies:	<ul style="list-style-type: none">• <i>In vitro</i>• Rodents• Non-primate non-rodent mammals	

Click on the above structure for additional information in [PubChem](#).

¹ National Center for Biotechnology Information, NLM, NIH, Bethesda, MD; Email: MICAD@ncbi.nlm.nih.gov.

✉ Corresponding author.

NLM Citation: Leung K. 4-(2-(4-(4-[¹⁸F]Fluoro-butyl)-phenyl)ethoxy) quinazoline. 2011 Jun 15 [Updated 2012 Jan 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.

Background

[PubMed]

Lipophilic cations are capable of passing through biological membranes by passive diffusion into the cytoplasm and mitochondria of cells in response to large negative plasma and mitochondrial membrane potentials. ^{99m}Tc -2-Methoxyisobutylisonitrile (^{99m}Tc -MIBI) and ^{99m}Tc -tetrofosmin are delocalized lipophilic cations, which are rapidly taken up into cells driven by metabolic demand and membrane potential (1-4). They are used as myocardial-perfusion single-photon emission computed tomography agents and as tumor-imaging agents. However, the high accumulation of Tc tracers in the lung and liver may interfere with the detection of flow abnormalities in the myocardium. More recently, positron emission tomography (PET) imaging has emerged as an alternative approach to evaluate myocardial blood flow with the use of positron-emitting radionuclides (e.g., $^{82}\text{RbCl}$, $^{13}\text{NH}_3$, and H_2^{15}O). However, the majority of these radiotracers exhibit short physical half-lives (<10 min). Lipophilic cations such as [^{11}C]triphenylmethylphosphonium ([^{11}C]TPMP) (5) and 4- ^{18}F fluorobenzyl-triphenylphosphonium ([^{18}F]FBnTP) have been investigated as PET agents for myocardial and tumor imaging (6).

Mitochondrial complex I (MCI) of the mammalian electron transfer chain is composed of at least 43 protein subunits, of which seven are encoded by mitochondrial DNA (7). MC-I catalyzes the transfer of electrons from NADH to ubiquinone and translocates protons from the mitochondrial matrix to the intermembrane space to generate ATP and thus the energy supply of the cell. MC-I may also play direct roles in the mitochondrial permeability transition and in cell death pathways. Myocardium has a high mitochondrial content because of high energy usage. 4-(2-(4-(4- ^{18}F Fluoro-butyl)-phenyl)ethoxy)quinazoline ([^{18}F]RP1003) has been found to be a potent MC-I inhibitor with a hydrophobic heterocyclic fenazaquin (8) and its use as a PET agent for imaging myocardium is being studied.

Related Resource Links:

- Chapters in MICAD ([MCI](#))
- Gene information in NCBI ([MCI](#))
- Articles in Online Mendelian Inheritance in Man (OMIM) ([MCI](#))
- Clinical trials ([MCI](#))

Synthesis

[PubMed]

[^{18}F]RP1003 was prepared as described by Yu et al. (8). [^{18}F]Fluoride/Kryptofix 2.2.2/ K_2CO_3 and the tosylate precursor were heated in acetonitrile for 30 min at 90°C, followed by high-performance liquid chromatography purification. Total synthesis time was 90

min. Radiochemical purity was >90%, with specific activities of 27.8–55.5 GBq/μmol (0.75–1.5 Ci/μmol) at the end of synthesis.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Yu et al. (8) reported that RP1003 inhibited NADH oxidation by bovine heart submitochondrial particles with a 50% inhibition concentration (IC₅₀) value of 3.7 nM. The IC₅₀ value of the known MC-I inhibitor rotenone was 18.2 nM.

Animal Studies

Rodents

[PubMed]

Yu et al. (8) performed *ex vivo* biodistribution studies of [¹⁸F]RP1003 in rats ($n = 10$). [¹⁸F]RP1003 accumulated mainly in the heart, with $3.52 \pm 0.36\%$ injected dose/g (ID/g) and $2.68 \pm 0.20\%$ ID/g at 15 min and 60 min after injection, respectively. Retention of [¹⁸F]RP1003 in the heart was good, with some washout. The heart/blood, heart/lung, heart/liver, and heart/femur ratios were 33.5, 11.1, 1.9, and 5.8 at 60 min after injection, respectively. The uptake in the femur was 0.46% ID/g at 60 min, indicating little defluorination of [¹⁸F]RP1003. For comparison, heart accumulation of ^{99m}Tc-sestamibi was 2.0% ID/g at 60 min, with a heart/lung ratio of 5.9 at 60 min after injection. PET imaging showed that [¹⁸F]RP1003 accumulated mainly in the heart and liver with low accumulation in the lung. Good myocardial images were observed at 25–35 min after injection, with little interference from the lung or liver at 55–60 min. No blocking experiment was performed. The first pass extraction efficiency was not addressed.

Other Non-Primate Mammals

[PubMed]

Yu et al. (8) performed PET imaging studies of [¹⁸F]RP1003 in rabbits ($n = 6$). [¹⁸F]RP1003 accumulated mainly in the myocardium within minutes after injection, with some interference from the lung and liver at 5–15 min after injection. Retention of [¹⁸F]RP1003 in the heart was good and exhibited some washout, whereas the retention was much lower in the liver. Accumulation of [¹⁸F]RP1003 in the heart was clearly visualized at 65 min after injection, with no interference from the lung and liver accumulation of [¹⁸F]RP1003.

Non-Human Primates

[PubMed]

No publication is currently available.

Human Studies

[PubMed]

No publication is currently available.

References

1. Chernoff D.M., Strichartz G.R., Piwnica-Worms D. *Membrane potential determination in large unilamellar vesicles with hexakis(2-methoxyisobutylisocyanide)technetium(I)*. Biochim Biophys Acta. 1993;1147(2):262–6. PubMed PMID: 8476920.
2. Chiu M.L., Kronauge J.F., Piwnica-Worms D. *Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisocyanide) technetium(I) in cultured mouse fibroblasts*. J Nucl Med. 1990;31(10):1646–53. PubMed PMID: 2213187.
3. Molteni S.N., Seregini E., Botti C., Martinetti A., Ferrari L., Crippa F., Bombardieri E. *The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation*. Anticancer Res. 1999;19(1A):255–9. PubMed PMID: 10226551.
4. Younes A., Songadele J.A., Maublant J., Platts E., Pickett R., Veyre A. *Mechanism of uptake of technetium-tetrofosmin. II: Uptake into isolated adult rat heart mitochondria*. J Nucl Cardiol. 1995;2(4):327–33. PubMed PMID: 9420807.
5. Krause B.J., Szabo Z., Becker L.C., Dannals R.F., Scheffel U., Seki C., Ravert H.T., Dipaola A.F. Jr, Wagner H.N. Jr. *Myocardial perfusion with [11C]methyl triphenyl phosphonium: measurements of the extraction fraction and myocardial uptake*. J Nucl Biol Med. 1994;38(3):521–6. PubMed PMID: 7865551.
6. Madar I., Ravert H.T., Du Y., Hilton J., Volokh L., Dannals R.F., Frost J.J., Hare J.M. *Characterization of Uptake of the New PET Imaging Compound 18F-Fluorobenzyl Triphenyl Phosphonium in Dog Myocardium*. J Nucl Med. 2006;47(8):1359–1366. PubMed PMID: 16883017.
7. Lenaz G., Fato R., Genova M.L., Bergamini C., Bianchi C., Biondi A. *Mitochondrial Complex I: structural and functional aspects*. Biochim Biophys Acta. 2006;1757(9-10):1406–20. PubMed PMID: 16828051.
8. Yu M., Guaraldi M., Kagan M., Mistry M., McDonald J., Bozek J., Yalamanchili P., Hayes M., Azure M., Purohit A., Radeke H., Casebier D.S., Robinson S.P. *Assessment of 18F-labeled mitochondrial complex I inhibitors as PET myocardial perfusion imaging agents in rats, rabbits, and primates*. Eur J Nucl Med Mol Imaging. 2009;36(1):63–72. PubMed PMID: 18716773.